Acquisition by Michael Poirier of 14437 shares of Qualigen Therapeutics at 2.5405 subject to Rule 16b-3

Read at macroaxis.com

Published over six months ago View all stories for Qualigen Therapeutics | Qualigen Therapeutics Hype Analysis

Acquisition of 14437 warrant (right to buy) at 2.5405 of Qualigen Therapeutics by Michael Poirier on 14th of April 2024. This event was filed by Qualigen Therapeutics with SEC on 2020-05-22. Statement of changes in beneficial ownership - SEC Form 4

We analyze Qualigen Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Qualigen Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Qualigen Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Qualigen Therapeutics stock to make a market-neutral strategy. Peer analysis of Qualigen Therapeutics could also be used in its relative valuation, which is a method of valuing Qualigen Therapeutics by comparing valuation metrics with similar companies.

Check out Qualigen Therapeutics Hype Analysis, Qualigen Therapeutics Correlation and Qualigen Therapeutics Performance. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.